twoplus fertility vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Singapore at-home fertility applicator for natural conception avoiding costly IVF/IUI; YC S20 $5.3M Monk's Hill Ventures-backed revenue-generating 2024 in SG/UK/US competing with Mosie Baby and Natalist for consumer fertility health products.
About
Twoplus Fertility is a Singapore-based consumer fertility health company — backed by Y Combinator (S20) with $5.3 million raised including a $5.15 million seed round led by Monk's Hill Ventures in May 2022 — providing couples experiencing difficulty conceiving with at-home fertility products designed as non-invasive, affordable alternatives to clinical fertility treatments, starting with the Twoplus Sperm Guide applicator (an at-home cervical cap applicator that positions sperm closer to the cervix during natural conception attempts, increasing the probability of fertilization for couples with mild male factor infertility or unexplained subfertility). Founded in 2019 by Prusothman Raja and Benjamin Tee, Twoplus became revenue-generating in 2024 and distributes products in Singapore, the United Kingdom, and the United States.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.